Hepatol Int (2017) 11 (Suppl 1):S1–S1093 DOI 10.1007/s12072-016-9783-9 AB STRACTS Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China Asian Paciﬁc Association for the Study of the Liver 2017 achieved by 100% (7/7) of patients with prior PI failure; 100% (42/42) Plenary Presentation with HCV/HIV coinfection; 91% (63/69) with advanced ﬁbrosis (in- cludes 3 PI failures, 10 coinfections, 12 post-transplant); 90% (54/60) 17 February 2017 (Friday) with cirrhosis (includes 4 coinfections); 91% (20/22) post-liver trans- Plenary Presentation 01 plant, and 100% (125/125) with no/mild ﬁbrosis. By HCV genotype, 15:45–17:15 98% (49/50) with GT-1b, 93% (13/14) with GT-2, 94% (179/190) with GT-3, and a single patient with GT-6 achieved SVR. Baseline NS5A RAS were detected in 13% (33/257) of patients. SVR was achieved in 85% (28/33) of patients with NS5A RAS: 100% (6/6) GT-1b patients PL001 with L31 M or Y93H, 75% (3/4) GT-2 with L31 M, 82% (18/22) of GT- 3 with A30 K or Y93H (including all of 8 with no/mild ﬁbrosis), and in Impact of baseline NS5A polymorphisms on sustained virologic the single GT-6 patient with R30S. NS5A RAS were detected at relapse response rates to treatment with daclatasvir plus sofosbuvir in all
Hepatology International – Springer Journals
Published: Feb 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud